Ac-SDKP: A Literature Course on What the Published Studies Report

Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is one of the most studied endogenous tetrapeptides in fibrosis research, yet almost all of the published work sits in animals, isolated cells and review articles rather than in clinical trials. This course is organised into six modules that follow the literature itself: what the molecule is, how its mechanism is described, what individual studies reported, how adverse events appear in publications, what pharmacokinetic information exists, and how the compound is classified by regulators. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or treatment decision. Nothing here is a protocol, a recommendation, or a claim of benefit.

Module 1 — What Ac-SDKP Is and How It Has Been Studied

Ac-SDKP is a four-amino-acid peptide (serine–aspartate–lysine–proline) carrying an acetyl group on its N-terminus. It is not a synthetic invention in origin: reviews describe it as an endogenous peptide generated in the body from the N-terminal region of thymosin beta-4 (Tβ4), the actin-sequestering protein abundant in many tissues, and the enzyme responsible for that release is prolyl oligopeptidase (POP), sometimes written prolyl endopeptidase, as summarised in a review of the Tβ4–POP–Ac-SDKP axis in organ fibrosis. Because of that upstream relationship, much of the Ac-SDKP literature is written as part of a pathway story rather than about an isolated drug candidate, a framing made explicit in a 2019 review asking whether the Tβ4–Ac-SDKP pathway has relevance for the cardiovascular system.

Class and naming

• Class: endogenous short peptide (tetrapeptide); studied as an anti-fibrotic and anti-inflammatory mediator rather than as a hormone or growth factor.
• Common designations: Ac-SDKP, AcSDKP, N-acetyl-Ser-Asp-Lys-Pro.
• Upstream precursor: thymosin beta-4, cleaved by prolyl oligopeptidase, as described in fibrosis-axis reviews (PMID 36362069).
• Principal degrading enzyme: the N-terminal catalytic domain of angiotensin-converting enzyme (ACE), a point emphasised in a review of Ac-SDKP synthesis and its role in ACE inhibition.

Forms that appear in the literature

Three forms recur. First, the native acetylated tetrapeptide, used in most animal and cell experiments. Second, radiolabelled analogues built for binding work — for example, the iodinated probe used in a study that characterised and localised Ac-SDKP binding sites with 125I-labelled Hpp-Aca-SDKP in rat cardiac fibroblasts. Third, engineered stability variants: researchers described a long-acting isomer of Ac-SDKP in a study of pulmonary fibrosis and SRPK1-mediated signalling, which exists precisely because the native peptide is short-lived.

How it has been studied

The evidence base is built from rodent disease models (cardiac, renal, pulmonary and neurological), cultured fibroblasts and inflammatory cells, one published meta-analysis of animal pulmonary fibrosis experiments, and a series of narrative reviews. Reviews have framed Ac-SDKP as a potential target molecule in research on heart, kidney and brain, and a Chinese-language review compiled its biological effects and mechanisms across organ systems.

Limits of the evidence (Module 1): definitions and biochemistry are well agreed upon, but the literature reviewed here contains no controlled human efficacy trials. Reviews repeatedly use the language of "potential" and "therapeutic possibility", which is a statement about research direction, not about established clinical use.

Module 2 — Mechanism as Described in the Literature

Mechanistic accounts of Ac-SDKP cluster around four themes.

1. An ACE-regulated peptide

Ac-SDKP is hydrolysed preferentially by the ACE N-domain, so circulating and tissue levels rise when ACE is pharmacologically inhibited; a pharmacology review framed this relationship as central to interpreting Ac-SDKP's anti-inflammatory profile and its discussion in hypertension and cardiovascular disease research. That same review covered how the peptide is synthesised and why ACE inhibition is difficult to separate from Ac-SDKP accumulation when interpreting experimental results.

2. Anti-fibrotic signalling

Across organ systems, reviews describe Ac-SDKP as interfering with profibrotic signalling — most commonly the TGF-β/Smad pathway and fibroblast-to-myofibroblast transition — in the context of the Tβ4–POP–Ac-SDKP axis in organ fibrosis. At the experimental level, one study reported that a long-acting isomer attenuated pulmonary fibrosis through SRPK1-mediated inhibition of PI3K/AKT and Smad2 signalling, naming a specific kinase-linked route rather than a generic anti-fibrotic effect.

3. Anti-inflammatory actions

Reviews characterise Ac-SDKP as an anti-inflammatory peptide, describing reduced inflammatory cell infiltration and cytokine signalling in cardiovascular models (PMID 29990624), and a review of biological effects and mechanisms collated similar observations across tissues (PMID 36882283).

4. Binding and cellular targets

The receptor question is unsettled. A cardiac fibroblast study used a radioiodinated analogue and characterised and localised specific Ac-SDKP binding sites in rat cardiac fibroblasts, which is the closest the verified literature comes to identifying a defined cellular target. Reviews of the cardiovascular pathway continue to discuss downstream effects on fibroblasts, endothelial cells and inflammatory cells rather than a single cloned receptor (PMID 30854877).

Limits of the evidence (Module 2): mechanism is inferred largely from animal and cell systems, and the ACE overlap is a persistent confounder because Ac-SDKP rises whenever ACE is inhibited. No paper in this set demonstrates that a named receptor fully accounts for the reported effects in intact humans.

Module 3 — Reported Outcomes, Study by Study

The table below summarises what each verified paper examined and what it reported. No doses are listed because the verified set does not supply dose details within the scope permitted for this page.

Read as a whole, the strongest experimental signal in this set concerns lung fibrosis models, where a meta-analysis reported consistent inhibition of fibrosis across animal studies (PMID 37248179) and a mechanistic study reported pathway-level findings with a stabilised isomer (PMID 33135306). Cardiac and renal claims rest mostly on reviews rather than on primary trials in this verified set.

Limits of the evidence (Module 3): animal fibrosis models are induced artificially and on short timelines, meta-analyses of animal data inherit the publication bias and reporting gaps of the underlying experiments, and none of these reports establishes an outcome in people. No benefit in humans should be inferred from any row above.

Module 4 — Ac-SDKP Side Effects: What Studies Report

The honest summary is that the verified literature is not a safety literature. The reviews in this set are written around mechanism and therapeutic hypothesis, not around tolerability tables: a review of Ac-SDKP's role in ACE inhibition and cardiovascular disease discussed the peptide's anti-inflammatory profile and therapeutic potential without presenting a characterised human adverse-event dataset (PMID 29990624), and the cardiovascular pathway review similarly framed unresolved questions about relevance rather than reporting a safety profile (PMID 30854877).

Where the literature does raise caution, it is indirect and mechanistic:

• Pathway breadth. Because Ac-SDKP arises from thymosin beta-4 via prolyl oligopeptidase and acts on fibroblast and inflammatory signalling in several organs at once, reviews of the Tβ4–POP–Ac-SDKP axis describe effects that are not organ-selective — a property that mechanistically complicates any assumption of a narrow action.
• Entanglement with ACE inhibition. Since ACE degrades the peptide, changes in Ac-SDKP levels occur alongside the broader haemodynamic and biochemical effects of ACE inhibitors, which the synthesis-and-ACE review treated as inseparable in interpretation (PMID 29990624).
• Broad biological activity. A review of Ac-SDKP's biological effects and mechanisms catalogued actions across multiple systems (PMID 36882283), and a further review extended the discussion to heart, kidney and brain (PMID 26350537); breadth of activity is not itself an adverse event, but it means untested off-target consequences cannot be ruled out from the published record.

Limits of the evidence (Module 4): absence of published adverse events in mechanistic animal studies and narrative reviews is not evidence of safety. None of the verified papers was designed as a toxicology study, none reports systematic dose-limiting toxicity, and no long-term human safety data appear in this set.

Module 5 — Pharmacokinetics Where Data Exist

Pharmacokinetic detail in the verified literature is sparse but directionally clear. The dominant PK fact is enzymatic: Ac-SDKP is a preferred substrate of the ACE N-terminal domain, so its clearance is tied to ACE activity, a relationship placed at the centre of a review of its synthesis and role in ACE inhibition. Formation kinetics run in the opposite direction: generation depends on prolyl oligopeptidase acting on thymosin beta-4, as described in the Tβ4–POP–Ac-SDKP axis review. Levels of the peptide are therefore a balance between POP-dependent production and ACE-dependent destruction.

The clearest practical consequence of rapid degradation is the development of stability-engineered analogues: researchers designed a long-acting isomer specifically to extend activity, and the study reported that this isomer attenuated pulmonary fibrosis via SRPK1-mediated PI3K/AKT and Smad2 pathway inhibition. Separately, tissue-level distribution questions were approached indirectly through radioligand work, where an iodinated analogue was used to localise binding sites in rat cardiac fibroblasts.

Limits of the evidence (Module 5): the verified set contains no human plasma concentration-time curves, no bioavailability comparison across routes of administration, and no formal half-life, volume-of-distribution or metabolite-profiling data within the scope citable here. PK statements above are qualitative and enzyme-based, not quantitative.

Module 6 — Regulatory Status, Stated Factually

Regulatory facts about Ac-SDKP can be described without interpretation:

• No approved Ac-SDKP drug product. There is no Ac-SDKP medicine approved by the US Food and Drug Administration or the European Medicines Agency for any indication. The literature discusses it as a research molecule and a "potential target", the phrasing used in a review of its relevance to heart, kidney and brain research (PMID 26350537).
• Research-use-only status. Synthetic Ac-SDKP and its analogues are supplied for laboratory research and are labelled research-use-only, meaning they are not authorised for administration to humans and are not manufactured to pharmaceutical quality standards required of medicines.
• Compounding. Under US law, compounding pharmacies may prepare drugs from bulk substances only where the substance meets specific statutory criteria; peptides that are neither components of approved drugs nor on the applicable FDA bulk-substances lists fall outside permitted compounding. Ac-SDKP is not an approved active ingredient, and the verified literature contains no clinical development programme supporting such use.
• Related pathway drugs. ACE inhibitors are approved medicines and raise endogenous Ac-SDKP as a consequence of N-domain inhibition (PMID 29990624); that regulatory approval belongs to the ACE inhibitors themselves, not to Ac-SDKP.

Limits of the evidence (Module 6): regulatory classification changes over time and varies by jurisdiction, and this module is a factual summary rather than legal or medical guidance. The status of a molecule in research supply chains says nothing about whether the underlying science supports any use in people.

What the Studies Did Not Test

Closing a course on Ac-SDKP honestly means naming the gaps in the verified literature:

1. Human efficacy. No randomised controlled trial of Ac-SDKP appears in this set; cardiac, renal and pulmonary conclusions were drawn from animal models, cell work and reviews (PMID 30854877, PMID 37248179).
2. Human safety and long-term exposure. Neither cumulative-exposure toxicology nor systematic adverse-event collection was reported by the reviews summarising the peptide's biological effects (PMID 36882283).
3. Dose-response in humans. No human dose-ranging data were presented in the verified papers, and animal dosing in this set cannot be extrapolated.
4. Route and formulation comparisons. The literature here describes experimental administration and a stability-engineered isomer (PMID 33135306) without comparative formulation studies in people.
5. Combination use. Interactions with ACE inhibitors are discussed mechanistically (PMID 29990624) but were not tested as a clinical combination strategy in this set.
6. Hard clinical endpoints. Reported outcomes were histological and molecular markers of fibrosis and inflammation, not survival, hospitalisation or organ-function outcomes in patients; even the infarction review framed cardiac healing as therapeutic potential rather than demonstrated benefit (PMID 17083265).

Ac-SDKP remains an interesting endogenous peptide with a coherent mechanistic story and a preclinical evidence base concentrated in fibrosis research. It is not an approved therapy, and the published record does not support conclusions about use in humans.

References

• Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system? (Canadian Journal of Physiology and Pharmacology, 2019)
• The Role of Tβ4-POP-Ac-SDKP Axis in Organ Fibrosis (International Journal of Molecular Sciences, 2022)
• Review on biological effects and mechanism of Ac-SDKP (Chinese Journal of Industrial Hygiene and Occupational Diseases, 2023)
• N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain (Current Pharmaceutical Design, 2015)
• The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases (Pharmacological Research, 2018)
• Therapeutic potential of thymosin-beta4 and its derivative N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) in cardiac healing after infarction (American Journal of Cardiovascular Drugs, 2006)
• Meta-analysis of Ac-SDKP inhibition of pulmonary fibrosis in animal models (Chinese Journal of Industrial Hygiene and Occupational Diseases, 2023)
• A long-acting isomer of Ac-SDKP attenuates pulmonary fibrosis through SRPK1-mediated PI3K/AKT and Smad2 pathway inhibition (IUBMB Life, 2020)
• Characterization and localization of Ac-SDKP receptor binding sites using 125I-labeled Hpp-Aca-SDKP in rat cardiac fibroblasts (American Journal of Physiology. Heart and Circulatory Physiology, 2007)